NCT05523245 Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI
| NCT ID | NCT05523245 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Condition | Rectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,700 participants |
| Start Date | 2022-06-24 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,700 participants in total. It began in 2022-06-24 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Establish a deep learning model based on multi-parameter magnetic resonance imaging to predict the efficacy of neoadjuvant therapy for locally advanced rectal cancer.This study intends to combine DCE with conventional MRI images for DL, establish a multi-parameter MRI model for predicting the efficacy of CRT, and compare it with the DL and non-artificial quantitative MRI diagnostic model constructed by conventional MRI to evaluate the role of DL in MRI predicting CRT. And this study also tries to build a DL platform to assess the efficacy of LARC neoadjuvant radiotherapy and chemotherapy, accurately assess patients' complete respose (pCR) after CRT, and provide an important basis for guiding clinical decision-making.
Eligibility Criteria
Inclusion Criteria: * Clinical suspicion or colonoscopic pathology of rectal cancer * Age over 18 years * Informed consent and signed informed consent form Exclusion Criteria: * Poor magnetic resonance image quality, such as severe artifacts * Previous treatment for rectal cancer * History or combination of other malignant tumours * Not Locally Advanced Rectal Cancer (LARC) * Not received neoadjuvant therapy or not completed neoadjuvant therapy * No surgery * Time interval between MRI and surgery was more than 2 weeks * Patients were lost to follow-up and voluntarily withdrew from the study due to adverse reactions or other reasons
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05523245 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05523245 currently recruiting?
Yes, NCT05523245 is actively recruiting participants. Contact the research team at mengxch3@mail.sysu.edu.cn for enrollment information.
Where is the NCT05523245 trial being conducted?
This trial is being conducted at Guangzhou, China, Guangzhou, China, Guangzhou, China, Zhuhai, China.
Who is sponsoring the NCT05523245 clinical trial?
NCT05523245 is sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. The trial plans to enroll 1,700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.